Not Signed In - ZymoGenetics And Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial In Patients With Lupus
Tue, 14 Nov 2006 08:00 AM EST
... ZymoGenetics, Inc. (Nasdaq: ZGEN) and Serono (virt-x: SEO and NYSE: SRA) today presented positive results at the American College of Rheumatology (ACR) annual meeting from a Phase 1b study in systemic lupus erythematosus (SLE) patients treated with atacicept(1). The results showed that atacicept was well tolerated across all dose levels and schedules in the study. [click link for full article] ...
Related Topics
- Clinical Trials
- Lupus Anticoagulant
- Lupus
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Carcinogens
- Tarceva
- Surgeon General's Reports on Tobacco
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Tb
- Bevacizumab Injection
- Seizures (in about half of patients)
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Crohn's Disease
email this page
print this page
bookmark this page
feedback on this page
